+

WO2008136438A1 - 遺伝子治療用ウイルスベクター - Google Patents

遺伝子治療用ウイルスベクター Download PDF

Info

Publication number
WO2008136438A1
WO2008136438A1 PCT/JP2008/058132 JP2008058132W WO2008136438A1 WO 2008136438 A1 WO2008136438 A1 WO 2008136438A1 JP 2008058132 W JP2008058132 W JP 2008058132W WO 2008136438 A1 WO2008136438 A1 WO 2008136438A1
Authority
WO
WIPO (PCT)
Prior art keywords
viral vector
gene
chemokine
gene therapy
cytokine
Prior art date
Application number
PCT/JP2008/058132
Other languages
English (en)
French (fr)
Inventor
Kenzaburo Tani
Hiroyuki Inoue
Makoto Inoue
Hiroaki Kinoh
Mamoru Hasegawa
Original Assignee
Kyushu University, National University Corporation
Dnavec Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation, Dnavec Corporation filed Critical Kyushu University, National University Corporation
Priority to US12/597,567 priority Critical patent/US20100203027A1/en
Priority to CA002685417A priority patent/CA2685417A1/en
Priority to JP2009512999A priority patent/JPWO2008136438A1/ja
Priority to EP08752166A priority patent/EP2143794A1/en
Publication of WO2008136438A1 publication Critical patent/WO2008136438A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明は、導入操作が簡便であり、且つin vivoにおいて十分の目的遺伝子発現が得られる安全な遺伝子治療用のウイルスベクターを提供することを目的とする。 　本発明により、顆粒球マクロファージコロニー刺激因子(GM-CSF)等のヘパリン結合性を有するサイトカイン並びにTARC及びRANTES等のケモカインを、マイナス鎖RNAウイルスをベースとしたウイルスベクターを用いてin vivoにおいて発現させた場合、抗腫瘍効果を示すと共に、従来のアデノウイルスベクターを用いた場合よりも優れた防護効果を誘導することが見出された。そこで、本発明は、サイトカイン遺伝子及びケモカイン遺伝子を含むマイナス鎖RNAウイルスベクターに関するものである。当該ウイルスベクターは、癌、特に転移性癌に対する処置に適するものである。また、本発明により、そのようなウイルスベクターを含む組成物、及びそれらを利用した遺伝子治療法も提供される。
PCT/JP2008/058132 2007-04-27 2008-04-25 遺伝子治療用ウイルスベクター WO2008136438A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/597,567 US20100203027A1 (en) 2007-04-27 2008-04-25 Viral vector for gene therapy
CA002685417A CA2685417A1 (en) 2007-04-27 2008-04-25 Viral vector for gene therapy
JP2009512999A JPWO2008136438A1 (ja) 2007-04-27 2008-04-25 遺伝子治療用ウイルスベクター
EP08752166A EP2143794A1 (en) 2007-04-27 2008-04-25 Viral vector for gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-119130 2007-04-27
JP2007119130 2007-04-27

Publications (1)

Publication Number Publication Date
WO2008136438A1 true WO2008136438A1 (ja) 2008-11-13

Family

ID=39943545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058132 WO2008136438A1 (ja) 2007-04-27 2008-04-25 遺伝子治療用ウイルスベクター

Country Status (5)

Country Link
US (1) US20100203027A1 (ja)
EP (1) EP2143794A1 (ja)
JP (1) JPWO2008136438A1 (ja)
CA (1) CA2685417A1 (ja)
WO (1) WO2008136438A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322611B1 (en) * 2008-07-16 2016-06-01 IP Pharma Co., Ltd. Method for production of reprogrammed cell using chromosomally unintegrated virus vector
US20140030218A1 (en) 2011-01-05 2014-01-30 Imperial Innovations Limited Treatment And Screening
CN102772791A (zh) * 2011-05-12 2012-11-14 天津泽世德生物医药有限公司 一种肿瘤疫苗及其制备方法
CN116196405A (zh) * 2019-12-31 2023-06-02 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6230752B2 (ja) 1984-08-09 1987-07-03 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
JPS6230753B2 (ja) 1984-08-10 1987-07-03 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
JPS6233879B2 (ja) 1984-08-09 1987-07-23 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
WO1997032010A1 (fr) 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Procede pour la purification et l'elimination de virus
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO2000070070A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
WO2000070055A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018223A1 (fr) 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2003025570A1 (en) 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2005071092A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
JP2006193433A (ja) 2005-01-11 2006-07-27 Kao Corp ピロリジン誘導体の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
US6514728B1 (en) * 1998-11-09 2003-02-04 Nippon Biocaptal Limited Process for preparation of cytokines using Sendai virus expression system
KR20060129013A (ko) * 2004-01-13 2006-12-14 가부시키가이샤 디나벡크 겐큐쇼 면역자극성 사이토카인을 코드하는 마이너스 가닥 ｒｎａ 바이러스 벡터를 사용하는 종양의 유전자 치료

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6230752B2 (ja) 1984-08-09 1987-07-03 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
JPS6233879B2 (ja) 1984-08-09 1987-07-23 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
JPS6230753B2 (ja) 1984-08-10 1987-07-03 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
WO1997032010A1 (fr) 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Procede pour la purification et l'elimination de virus
WO2000070070A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
WO2000070055A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001004272A1 (en) 1999-07-09 2001-01-18 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018223A1 (fr) 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2003025570A1 (en) 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2005071092A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
JP2006193433A (ja) 2005-01-11 2006-07-27 Kao Corp ピロリジン誘導体の製造方法

Non-Patent Citations (98)

* Cited by examiner, † Cited by third party
Title
"State-of-the-Art Technology Protocol in Neuroscience Research III, Molecular Neuron Physiology", 1993, KOSEISHA, pages: 153 - 172
"Techniques in Molecular Biology", 1983, MACMILLAN PUBLISHING COMPANY
ABE J ET AL., JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, 1995, pages 587 - 92
ABE J, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, 1995, pages 587 - 92
ABE J, WAKIMOTO H ET AL.: "Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, 1995, pages 587 - 92
ALTSCHUL, S. F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, S. F. ET AL., NATURE GENET, vol. 3, 1993, pages 266 - 272
ALTSCHUL, S. F. ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
ARAI, T. ET AL., J. VIROL, vol. 72, 1998, pages 1115 - 1121
ARAI, T. ET AL., J. VIROL., vol. 72, 1988, pages 1115 - 1121
ARAI, T. ET AL., J. VIROL., vol. 72, 1998, pages 1115 - 1121
ARAI, T. ET AL., J. VIROLOGY, vol. 72, 1998, pages 1115 - 1121
BARON, M.D.; BARRETT, T., J. VIROL., vol. 71, 1997, pages 1265 - 1271
BECHER B. ET AL., J CLIN INVEST., vol. 112, no. 8, 2000, pages 1186 - 91
BITZER, M. ET AL., J. GENE MED., vol. 5, 2003, pages 533 - 543
BRIDGEN, A.; ELLIOTT, R.M., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 15400 - 15404
BUNNELL, B.A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7739 - 7743
CALOS, M.P., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 3015
CHINNASAMY, D. ET AL., BLOOD, vol. 96, 2000, pages 1309 - 1316
CHU Y; XIA M; LIN Y ET AL.: "Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF", CANCER GENE THERAPY, vol. 13, 2006, pages 510 - 9
CHUCK, A.S., HUM. GENE THER., vol. 7, 1996, pages 743 - 750
CURR. OPIN. MOL. THER., vol. 7, no. 4, 2005, pages 346 - 352
DAYHOFF ET AL.: "Atlas of Protein Sequence and Structure", 1978, NATL. BIOMED. RES. FOUND.
DURBIN, A.P. ET AL., VIROLOGY, vol. 235, 1997, pages 323 - 332
ELLYARD JI; SIMSON L; PARISH CR.: "Th2-mediated anti-tumour immunity: friend or foe?", TISSUE ANTIGENS, vol. 70, 2007, pages 1 - 11
ELLYARD JI; SIMSON L; PARISH CR.: "Th2-mediated anti-tumour immunity: friend or foe?", TISSUE ANTIGENS., vol. 70, 2007, pages 1 - 11
FEHSE, B. ET AL., BR. J. HAEMATOL, vol. 102, 1998, pages 566 - 574
FUERST, T. R. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 8122 - 8126
FUERST, T.R. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 8122 - 8126
GARCIN, D. ET AL., EMBO J., vol. 14, 1995, pages 6087 - 6094
GIEZEMAN-SMITS, K.M. ET AL., CANCER RES., vol. 60, 2000, pages 2449 - 2457
HASAN, M. K. ET AL., J. GEN. VIROL., vol. 78, 1997, pages 2813 - 2820
HASAN, M. K. ET AL., J. GENERAL VIROLOGY, vol. 78, 1997, pages 2813 - 2820
HERRLINGER, U. ET AL., CANCER GENE THER., vol. 4, 1997, pages 345 - 352
HURWITZ, J.L. ET AL., VACCINE, vol. 15, 1997, pages 533 - 540
INOUE H. ET AL.: "Chemokine, TARC Oyobi RANTES wa GM-CSF Idenshi Donyu Saibo o Mochiita Gan Vaccine Ryoho ni Okeru Koshuyo Koka o Zokyo suru", BIOTHERAPY (19TH JAPAN SOCIETY FOR BIOLOGICAL THERAPY GAKUJUTSU SHUKAI SOKAI PROGRAM & SHOROKUSHU), vol. 20, no. SUPPL. 1, 2006, pages 116 + ABSTR. NO. O-2-2 *
INOUE H. ET AL.: "Non-transmissible SeV(dF)-transduced autologous GM-CSF cancer vaccine cells as a candidate for immune gene therapy", 66TH THE JAPANESE CANCER ASSOCIATION GAKUJUTSU SOKAI KIJI, 25 August 2007 (2007-08-25), pages 379 + ABSTR. NO. P-930 *
INOUE M ET AL., J. VIROLOGY, vol. 77, 2003, pages 3238 - 46
INOUE M ET AL., J. VIROLOGY., vol. 77, 2003, pages 3238 - 46
INOUE M; TOKUSUMI Y; BAN H ET AL.: "Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins", JOURNAL OF VIROLOGY, vol. 77, 2003, pages 3238 - 46, XP002986305, DOI: doi:10.1128/JVI.77.5.3238-3246.2003
IWADATE Y. ET AL.: "Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats", CLIN. CANCER RES., vol. 11, no. 10, 2005, pages 3821 - 3827, XP009077339 *
IWADATE, Y. ET AL., CANCER GENE THER., vol. 7, 2000, pages 1263 - 1269
IWADATE, Y. ET AL., CANCER RES., vol. 61, 2001, pages 8769 - 8774
IWADATE, Y. ET AL., INT. J. MOL. MED., vol. 10, 2002, pages 741 - 747
IWADATE, Y. ET AL., INT. J. ONCOL., vol. 23, 2003, pages 483 - 488
IWADATE, Y. ET AL., ONCOLOGY, vol. 54, 1997, pages 329 - 334
J. GENE MED., vol. 5, no. 7, 2003, pages 543 - 553
J. NEUROSURGERY, vol. 90, no. 6, 1999, pages 1115 - 1124
J. VIROLOGY, vol. 39, 1981, pages 519 - 528
JOURNAL OF VIROLOGY, vol. 67, no. 8, 1993, pages 4822 - 4830
KANEKO K. ET AL.: "A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic snydrome in severe hindlimb ischemia", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 290, 2006, pages H1484 - H1492, XP008121737 *
KATO, A. ET AL., EMBO J., vol. 16, 1997, pages 578 - 5 97
KATO, A. ET AL., EMBO J., vol. 16, 1997, pages 578 - 587
KATO, A. ET AL., GENES CELLS, vol. 1, 1996, pages 569 - 579
KATO, A. ET AL., J. VIROL., vol. 71, 1997, pages 7266 - 7272
KOJIMA T; YAMAZAKI K; TAMURA Y ET AL.: "Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice", HUMAN GENE THERAPY, vol. 14, 2003, pages 715 - 28, XP002990092, DOI: doi:10.1089/104303403765255129
KOLAKOFSKI, D. ET AL.: "rule of six", J. VIROL., vol. 72, 1998, pages 891 - 899
LAMB, R. A.; D. KOLAKOFSKY ET AL.: "Fields Virology", 1996, RAVEN PRESS, article "Paramywoxiridae: The viruses and their replication", pages: 1177 - 1204
LAMB, R.A.; KOLAKOFSKY, D.: "Fields of virology", vol. 2, 1996, LIPPINCOTT-RAVEN PUBLISHERS, article "Paramyxoviridae: The viruses and their replication", pages: 1177 - 1204
LAWSON, N. D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 4477 - 4481
LI, FL.-O. ET AL., J. VIROL., vol. 74, no. 14, 2000, pages 6564 - 6569
LI, H.-O. ET AL., J. VIROLOGY, vol. 74, 2000, pages 6564 - 6569
MADDEN, T. L. ET AL., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141
METHODS ENZYMOL., vol. 154, 1987, pages 367 - 382
MOLECULAR THERAPY, vol. 13, no. 1, May 2006 (2006-05-01), pages 185
MORIYA C. ET AL.: "Large quantity production with extreme convenience of human SDF-1alpha and SDF-1beta by a Sendai virus vector", FEBS LETTERS, vol. 425, 1998, pages 105 - 111, XP000887284 *
NAKAZAKI Y. ET AL.: "Serial Analysis of Gene Expression in Progressing and Regressing Mouse Tumors Implicates the Involvement of RANTES and TARC in Antitumor Immune Responses", MOLECULAR THERAPY, vol. 14, no. 4, 2006, pages 599 - 606, XP005624428 *
NAT. MED., vol. 3, 1997, pages 1354 - 1361
NAVIAUX, R. K. ET AL., J. VIROL., vol. 70, 1996, pages 5701 - 5705
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
PROC. NATL. ACAD. SCI. USA, vol. 96, no. 15, 1999, pages 8591 - 8596
RADECKE, F. ET AL., EMBO J., vol. 14, 1995, pages 5773 - 5784
RAMSBURG E. ET AL.: "A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals", JOURNAL OF VIROLOGY, vol. 79, 2005, pages 15043 - 15053, XP008121740 *
S. HENIKOFF; J.G. HENIKOFF, PROC. ACAD. NATL. SCI. USA, vol. 89, 1992, pages 10915 - 10919
SAITO ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 3816 - 3821
SAITO, I. ET AL., NUCL. ACID. RES., vol. 23, 1995, pages 3816 - 3821
SALGIA B.R ET AL.: "Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pages 624 - 630, XP002532178 *
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SAMPSON, J.H. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 10399 - 10404
SCHNELL. M. J. ET AL., EMBO J., vol. 13, 1994, pages 4195 - 4203
SELEH, M. ET AL., J. NATL. CANCER INST., vol. 91, 1999, pages 438 - 445
SHIBATA S. ET AL.: "Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation of Exogenous IFN-beta Gene", THE JOURNAL OF IMMUNOLOGY, vol. 177, 2006, pages 3564 - 3576, XP008121803 *
SHIBATA S; OKANO S; YONEMITSU Y ET AL.: "Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene", J HNMUNOL., vol. 177, 2006, pages 3564 - 76, XP008121803
SHIBATA S; OKANO S; YONEMITSU Y ET AL.: "Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene", J IMMUNOL., vol. 177, 2006, pages 3564 - 76, XP008121803
SHIOTANI A ET AL.: "Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector", GENE THER, vol. 8, no. 14, 2001, pages 1043 - 50
SHIRAKURA M. ET AL.: "Sendai virus vector-mediated gene transfer of glial cell line-derived neurotrophic factor prevents delayed neuronal death after transient global ischemia in gerbils", EXP. ANIM., vol. 52, 2003, pages 119 - 127, XP008121735 *
SILVESTRIS F ET AL., BR J HAEMATOL., vol. 122, no. 1, 2003, pages 39 - 52
SINGH M. ET AL.: "A recombinant measles virus expressing biologically active human interleukin-2", JOURNAL OF GENERAL VIROLOGY, vol. 80, 1999, pages 101 - 106, XP008121734 *
SOIFFER R; LYNCH T; MIHM M ET AL.: "Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma", PROC NATL ACAD SCI USA., vol. 95, 1998, pages 13141 - 6, XP002130323, DOI: doi:10.1073/pnas.95.22.13141
TANI K.: "Tokushu Idenshi Chiryo - Nanjisei Shikkan eno Saishin Senryaku Gan Idenshi Chiryo Kenkyu no Saizensen", EXPERIMENTAL MEDICINE, vol. 17, 1999, pages 2254 - 2259 *
TANI K; AZUMA M; NAKAZAKI Y ET AL.: "Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings", MOL THER., vol. 10, 2004, pages 799 - 816, XP004660624, DOI: doi:10.1016/j.ymthe.2004.07.001
TASHIRO, M.: "Virus Experiment Protocol", 1995, MEDICAL VIEW CO., LTD., pages: 68 - 73
TATIANA A ET AL., FEMS MICROBIOL LETT., vol. 174, 1999, pages 247 - 250
VERTUANI S ET AL.: "Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes", CANCER RESEARCH, vol. 63, 2003, pages 8006 - 13
WHELAN, S. P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8388 - 8392
YONEMITSU, Y.; KANEDA, Y.: "Molecular Biology of Vascular Diseases. Method in Molecular Medicine", 1999, HUMANA PRESS, article "Hemagglutinating virus of Japan-liposome-mediated gene delivery to vascular cells", pages: 295 - 306
YU, D. ET AL., GENES CELLS, vol. 2, 1997, pages 457 - 466
ZHANG, J.; MADDEN, T. L., GENOME RES., vol. 7, 1997, pages 649 - 656

Also Published As

Publication number Publication date
EP2143794A1 (en) 2010-01-13
US20100203027A1 (en) 2010-08-12
CA2685417A1 (en) 2008-11-13
JPWO2008136438A1 (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
Klingenberg et al. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
HK1109617A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c
WO2008136438A1 (ja) 遺伝子治療用ウイルスベクター
HK1139656A1 (en) Tetrahydrofuro [3,4-d] dioxolane compounds for use in the treatment of viral infections and cancer
WO2010081082A3 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
WO2005018555A3 (en) Lipid-modified immune response modifiers
WO2006026760A3 (en) 1-amino imidazo-containing compounds and methods
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2010111653A3 (en) Modulating ires-mediated translation
WO2011119925A3 (en) Synthetic herpes simplex viruses for treatment of cancers
WO2007076161A3 (en) Compounds with therapeutic activity
WO2010093843A3 (en) Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
MXPA02000490A (es) Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
WO2009061395A3 (en) Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
WO2008096811A1 (ja) 弱毒化マイナス鎖rnaウイルス
WO2005047478A3 (en) Compositions and methods for regulation of tumor necrosis factor-alpha
WO2006069064A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2006109071A3 (en) Vaccine against burkholderia infections
Arif et al. Silencing VDAC1 expression by siRNA inhibits cancer cell proliferation and tumor growth in vivo
WO2007038316A3 (en) Human cytomegalovirus latency promoting genes, related virus variants and methods of use
McGlynn et al. International liver cancer incidence trends
Tavana et al. p53 and DNA methylation suppress the TRAIN to cell death

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752166

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009512999

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2685417

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008752166

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12597567

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载